MedTrace Logo

Effect Of PF-06305591 On Capsaicin And Capsaicin/Heat-Induced Neurogenic Flare

NCT01797796 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2013-08-20

No results posted yet for this study

Summary

The purpose of this study is to examine the effect of PF-06305591 on capsaicin and capsaicin/heat-induced neurogenic flare.

Conditions

  • Healthy

Interventions

DRUG

PF-06305591

150 mg PF 06305591 will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.

OTHER

Capsaicin challenge

110 mg capsaicin cream (Axsain®) will be applied topically at each visit.

DRUG

Placebo

Placebo will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.

OTHER

Capsaicin challenge

110 mg capsaicin cream (Axsain®) will be applied topically at each visit.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01797796 on ClinicalTrials.gov